Epigenetics Diagnostic Market by Products (Reagents, Kits [ChIP Sequencing Kit, Whole Genomic Amplification Kit, Bisulfite Conversion Kit, RNA Sequencing Kit, and Others], Instruments, Enzymes, and Services), Technology (DNA Methylation, Histone Methylation, Histone Acetylation, Large Non-coding RNA, MicroRNA Modification, and Chromatin Structures), Applications (Oncology [Solid Tumors and Liquid Tumors] and Non-oncology [Inflammatory Diseases, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases, and Others]), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

The global epigenetics diagnostic market size is estimated to expand at a substantial CAGR during the forecast period, 2021 – 2028. The growth of the market is attributed to the rising prevalence of cancer and other chronic diseases, which is accelerated due to the increasing geriatric population.
 

Epigenetics is a part of the analysis of hereditary changes of gene expression; which means a characteristic shift is occurred without a change of genotype. Epigenetic alteration is a common and natural process, which is mainly influenced by a number of factors such as aging, climate or lifestyle, and disease state. Several continuing research continue to shed light on the role of epigenetics in a wide range of human illnesses and fatal diseases including cancer, heart disease, diabetes, and mental illnesses. Epigenetic treatment can be used to specifically affect certain pathways. Epigenetic medications and diagnostics, as well as other abnormal alterations of skin cells, liver cells, brain cells, and others, are used in early-stage cancer screening.

Epigenetic test kits are also used to detect diseases caused by early-stage epigenetic modifications to validate drug effectiveness during treatment. Centered on immunoprecipitation, they act by using modification-specific monoclonal antibodies. Epigenetic drugs are types of medicine widely adopted to cure various types of cancers as well as other diseases such as respiratory diseases and Alzheimer's disease. These drugs are divided into two categories: DNA methylation inhibitors and histone deacetylase inhibitors. The US Food and Drug Administration (FDA) has approved several cancer treatment medications to improve their treatment using chemotherapy sensitization, radiotherapy, and immune system modulation.

According to the National Institutes of Health (NIH), the total number of cancer deaths in the US is 171 per 100,000 men and women every year. With the growing number of chronic illness cases, several healthcare-based organizations are constantly focusing to improve their treatment methods. For instance, the Encyclopedia of DNA Elements (ENCODE) project was initiated by the National Human Genome Research Institute in the US with the aim of identifying all usable elements in the human genome series. The NIH-funded International Human Epigenome Consortium (IHEC) has been extensively providing the global epigenomic data that can be used by several medical researchers.

Market Trends, Drivers, Restraints, and Opportunities

• Rising prevalence of chronic illness and diseases related to hereditary or genotype of patients are key factors boosting the market growth.
• Extensive funding for research and product development under the initiatives of major organizations such as the International Human Epigenome Consortium (IHEC), the National Cancer Institute (NCI), and the National Institutes of Health (NIH) are expected to drive market growth.
• Rapid development of advanced healthcare facilities and diagnostic clinics to provide effective solution for epigenetics testing and offer reliable therapeutics solutions present major drivers for the market.
• Lack of experts or technicians handling the diagnostic process and lack of advanced medical facilities in developing countries act as key challenges that can hamper the market growth.
• Extensive R&D activities and wide adoption of innovative technology in the testing devices for epigenetics diagnostic are expected to create lucrative opportunities for the market players.

Scope of the Report

The report on the global epigenetics diagnostic market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Reagents segment to hold a key market share
Based on products, the global epigenetics diagnostic market is divided into reagents, kits, instruments, enzymes, and services. The kits segment is further divided into ChIP sequencing kit, whole genomic amplification kit, bisulfite conversion kit, RNA sequencing kit, and others. The reagents segment is anticipated to account for a key share of the market during the forecast period owing to wide adoption of the several reagents employed in the diagnostics. The most common epigenetic reagents are histone and DNA modifiers. Pyro Mark Q24 is one of the advanced reagents that offers advanced pyrosequencing composition to provide better real-time sequence-based identification and quantification than previously available. The existence of a variety of research tools help promote extensive research related to the RNA, protein, or cellular levels, which has resulted in epigenetic reagent advancement. The polymerase chain reaction developed a genomic platform. Epigenetic factors such as chromatin formation, DNA methylation, and non-coding RNAs are key areas that have impact on gene regulation. The demand for life sciences and analytical instruments is primarily influenced by the extensive use of reagents.

Meanwhile, the kits segment is expected to register a significant growth rate during the forecast period owing to wide demand for effective and accurate diagnostics kits. Many biotechnology firms provide ready-to-use kits for the identification of epigenetic modifications and these kits are also applied for nucleic acid purification, DNA methylation analysis, and identification of histone modifications by different enzymes.

DNA methylation segment to constitute a major market share
On the basis of technology, the market is divided into DNA methylation, histone methylation, histone acetylation, large non-coding RNA, microRNA modification, and chromatin structures. The DNA methylation segment is projected to constitute a major market share in the coming years owing to wide adoption of the technology. Methylation sensitive PCR refers to the process of sensitive bi-sulphite modification accompanied by PCR (MSP) and is the covalent addition of a methyl group to the cytosine ring that causes transcription to be inhibited. MSP variants include real-time PCR for methylation identification, methyl illumination, and quantitative analysis of methylated alleles. Currently, quantitative approaches for DNA methylation include allele-specific bi-sulphite sequencing, the southern process, bi-sulphite pyrosequencing, and bi-sulphite PCR accompanied by MALDI-TOF MS. Technological advancements are making it possible to determine locus-specific DNA methylation on a genome-wide scale.
 

Oncology segment is likely to dominate the market
Based on applications, the global global epigenetics diagnostic market is divided into oncology and non-oncology. The oncology segment is further bifurcated into solid tumors and liquid tumors; while, the non-oncology segment consists of inflammatory diseases, metabolic diseases, infectious diseases, cardiovascular diseases, and others. The oncology segment is anticipated to dominate the market in the coming years due to the rising prevalence of cancer worldwide as well as the rising number of deaths from tumors. Furthermore, the rapid launch of new products and the possible future commercialization of treatment and diagnostic products that are already in the pipeline are projected to boost the revenue share of the segment during the forecast period.

North America to exhibit a high CAGR
In terms of regions, the market is divided into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to exhibit a high CAGR during the forecast period owing to the presence of advanced technological facilities, successful campaigns, and constantly increasing geriatric population in the region. Moreover, factors such as improved healthcare facilities, government funding for ongoing epigenetic research activities, diligent research, and accurate diagnostic procedures are key drivers for the regional market growth. Furthermore, a vast range of popular fund-supported projects in the US present a key aspect to increase epigenetic research activities in a variety of diseases, including oncology and non-oncology diseases such as cardiovascular, metabolic, and inflammatory.

The market in Asia Pacific, however, is expected to grow at an impressive rate during the projected period owing to increasing disposable income, high unmet clinical needs of patients, increased knowledge about early detection, and the availability of appropriate care in emerging markets such as India and China. The region is emerging a leading market destination due to an increase in the number of cancer cases of different forms.